Show simple item record

dc.contributor.authorEivazy, P
dc.contributor.authorAtyabi, F
dc.contributor.authorJadidi-Niaragh, F
dc.contributor.authorAghebati Maleki, L
dc.contributor.authorMiahipour, A
dc.contributor.authorAbdolalizadeh, J
dc.contributor.authorYousefi, M
dc.date.accessioned2018-08-26T07:21:58Z
dc.date.available2018-08-26T07:21:58Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/46203
dc.description.abstractHigh-mobility group protein two (HMGA2), a nonhistone nuclear-binding protein and its downregulators; vimentin, matrix metallopeptidase-9 (MMP-9), and E-cadherin are shown to contribute to tumor progression and metastasis. Thus, in this study, we checked simultaneous delivery of HMGA-2 siRNA and the anticancer drug doxorubicin to enhance the anticancer treatment effects. For this purpose, we used MTT assay and real-time polymerase chain reaction (RT-PCR). Our results showed that dual delivery of Dox and HMGA-2 siRNA by trimethyl chitosan (TMC) significantly inhibited breast cancer cells growth. Additionally, the delivery of siRNA significantly silenced HMGA-2, vimentin, and MMP9 mRNAs, but led to overexpression of E-cadherin mRNA.
dc.language.isoEnglish
dc.relation.ispartofARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
dc.subjectBreast cancer
dc.subjectHMGA2
dc.subjectnanoparticle
dc.subjecttherapy
dc.titleThe impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231)
dc.typeArticle
dc.citation.volume45
dc.citation.issue5
dc.citation.spage889
dc.citation.epage896
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1080/21691401.2016.1185727


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record